PyRICo-P – Pyridostigmine to Reduce the duration of postoperative Ileus after Colorectal Surgery – a Phase II study.

The Royal Adelaide Hospital0 个研究点目标入组 15 人开始时间: 2020年11月24日最近更新: 2020年11月30日

适应症

试验速览

暂无简介。

•Adult patients (aged 18 or older) from Central Adelaide Local Health Network catchment area
•- Undergoing elective colorectal surgery (including large or small bowel resections for any indication or undergoing reversal of Hartmann's or loop-ileostomy closure or formation of a stoma
•- Able to give informed consent

•Under 18 years of age.
•Previous adverse reaction to pyridostigmine
•ASA >=4 due to the higher likelihood or morbidity and mortality, which may confound resulting data.
•Active inflammatory bowel disease
•Prolonged QT syndrome (greater than 0.43sec for males, 0.45 for females)
•Medications that are prescribed directly for their anti-cholinergic effects (e.g. Glycopyrrolate for drooling; amitriptyline for loose bowel actions);
•Asthma requiring regular medications
•Ischaemic heart disease or cardiac arrhythmias within the previous 12 months
•History of epilepsy
•History of Parkinson’s disease
•Hyperthyroidism
•Peptic ulcer disease
•Diagnosed pelvic disorders that may be a cause of constipation
•Moderate to severe renal impairment Creatinine clearance of < 30 ml/min
•CrCl ml/min = [140-age(years)] x bodyweight (kg) / R x serum creatinine (micromol/L)
•R = 0.815 for males, 0.85 for females
•History of bowel obstructions, strictures or history of any diseases affecting bowel transit (e.g. uncontrolled hypothyroidism, hypercalcaemia), irritable bowel syndrome (IBS), history of faecal incontinence)
•Inability to give consent or participate in post-operative assessments due to dementia, cognitive impairment and/or language barrier.

发起方

The Royal Adelaide Hospital